The company will not receive any proceeds from the resale or other disposition of the shares of common stock by the selling stockholders. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on DRMA: Biotech Alert: Searches spiking for these stocks today Dermata Therapeutics to prices 2M shares at $1.27 in private placement Dermata Therapeutics receives FDA approval for Xyngari proprietary name Dermata Therapeutics completes enrollment in DMT310 Phase 3 STAR-1 trial
